Sanofi’s biotechnology arm, Genzyme Corp., has initiated legal action against Sarepta Therapeutics, filing a complaint in Delaware federal court. The lawsuit, which was filed on Friday, accuses Sarepta of infringing on two of Genzyme’s patents related to the manufacturing of therapeutics for treating Duchenne muscular dystrophy. For further details on the case, you can review more information here.